Abstract:Alport syndrome (AS) is an inherited progressive disease caused by mutations in genes encoding for the 3, 4 and 5 chains, which are an essential component of type IV collagen and are required for formation of the glomerular basement membrane. However, the underlying etiology of AS remains largely unknown, and the aim of the present study was to examine the genetic mechanisms in AS. Induced pluripotent stem cells (iPSCs) were generated from renal tubular cells. The Illumina HiSeq 2000 system and iTRAQ-coupled 2D liquid chromatography-tandem mass spectrometry were used to generate the sequences of microRNAs (miRNAs), transcripts and proteins from AS-iPSCs. Integration of miRNA, transcript and protein expression data was used to construct regulatory networks and identify specific miRNA targets amongst the transcripts and proteins. Relative quantitative proteomics using iTRAQ technology revealed 383 differentially abundant proteins, and high-throughput sequencing identified 155 differentially expressed miRNAs and 1,168 differentially expressed transcripts. Potential miRNA targets were predicted using miRanda, TargetScan and Pictar. All target proteins and transcripts were subjected to network analysis with miRNAs. Gene ontology analysis of the miRNAs and their targets revealed functional information on the iPSCs, including biological process and cell signaling. Kyoto Encyclopedia of Genes and Genomes pathways analysis revealed that the transcripts and proteins were primarily enriched in metabolic and cell adhesion molecule pathways. In addition, the network maps identified hsa-miRNA (miR)-4775 as a prominent miRNA that was associated with a number of targets. Similarly, the prominent ELV-like protein 1-A and epidermal growth factor receptor (EGFR)-associated transcripts were identified. Reverse transcription-quantitative polymerase chain reaction analysis was used to confirm the upregulation of hsa-miR-4775 and EGFR. The integrated approach used in the present study provided a comprehensive molecular characterization of AS. The results may also further understanding of the genetic pathogenesis of AS and facilitate the identification of candidate biomarkers for AS.

Generation of Induced Pluripotent Stem Cell Line (Nckdi001-A) from a 19-Year-old Patient with a Novel COL4A5 Gene Mutation in Alport Syndrome

Generation of the Induced Pluripotent Stem Cell Line (Nckdi004-A) from a 17-Year-old Patient with Alport Syndrome Carriny a Homozygous Mutation in COL4A3 Gene

Establishment of the Induced Pluripotent Stem Cell Line (Nckdi005-A) from a Male Patient with Alport Syndrome Carrying a Homozygous Frameshift Mutation in the COL4A4 Gene.

Generation of Induced Pluripotent Stem Cell Line (Zzui007-A) from a 52-Year-old Patient with a Novel CHCHD2 Gene Mutation in Parkinson's Disease.

Establishment of Induced Pluripotent Stem Cell Line (Zzui009-A) from an Alzheimer's Disease Patient Carrying a PSEN1 Gene Mutation

Generation of an Induced Pluripotent Stem Cell Line from a Brugada Syndrome Patient Carrying SCN5A/c.3118G>C Mutation

Generation of an Induced Pluripotent Stem Cell Line (Shcdnri001-A) from a Patient with X-linked Alport Syndrome Carrying a Heterozygous P.g409s (c. 1225 G > A) Mutation in the COL4A5 Gene

Generation of Induced Pluripotent Stem Cell Line (Zzui0013-A) from a 65-Year-old Patient with a Novel MEOX2 Gene Mutation in Alzheimer's Disease.

Generation of an Induced Pluripotent Stem Cell Line from the Dermal Fibroblasts of a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy Carrying a PKP2/c.2489+1G > A Mutation

Generation of an induced pluripotent stem cell line from a patient carrying FBN1/c.6734 G > A mutation

Establishment of Induced Pluripotent Stem Cell Line (Zzui010-A) from an Alzheimer's Disease Patient Carrying an APP Gene Mutation.

Generation of Five Induced Pluripotent Stem Cell Lines with DMD/c.497G > T Mutation from Renal Epithelial Cells of a Duchenne Muscular Dystrophy Patient and a Recessive Carrier Parent

Generation of an induced pluripotent stem cell line from a patient carrying FBN1/c.6734 G > A mutation.

Generation of Induced Pluripotent Stem Cell Line, ZJUCHi002-A, from Charcot-Marie-Tooth Disease Type 2A (CMT2A) Patient with a Mutation of C.752c>t in MFN2

Establishment of an induced pluripotent stem cell line from a patient with X-linked Alport syndrome carrying a hemizygous splicing variant (NM_033380; c.929[exon 16]delG) in the collagen type IV alpha 5 chain gene

Generation of a Human Charcot-Marie-Tooth Disease Type 1B (CMT1B) Ipsc Line, ZJUCHi001-A, with a Mutation of C.292c>t in MPZ.

Generation of an induced pluripotent stem cell line from an Alstrom Syndrome patient with <i>ALMS1</i> mutation (c.3902C > A, c.6436C > T) and a gene correction isogenic iPSC line

Generation of an Induced Pluripotent Stem Cell Line from a Long QT Syndrome Patient Carrying KCNH2/1956C > A Mutation.

Generation of a Human Induced Pluripotent Stem Cell Line from a Female Patient Carrying LZTR1 Gene Mutation

Establishment of Microrna, Transcript and Protein Regulatory Networks in Alport Syndrome Induced Pluripotent Stem Cells

Generation of an induced pluripotent stem cell line (CSBZZUi001-A) from a female Alzheimer's patient carrying the PSEN1 709 T > C heterozygous mutation